The production rate of cortisol based on both the plasma clearance of the hormone (plasma production rate) and the urinary metabolite method (urinary production rate) was simultaneously measured in early or advanced breast cancer patients and in controls. Higher production of the hormone was observed by both these methods in patients with advanced breast cancer.
INTRODUCTION
In previous communications from this laboratory it has been reported that patients with advanced breast cancer have significantly raised plasma levels of 17- hydroxycorticoids and that this is mainly due to a raised production of the hormones since no abnormalities were observed in protein binding, metabolic clearance rate, distribution between pools or hepatic extraction (Deshpande, Hayward & Bulbrook, 1965;  Jensen, Deshpande, Bulbrook & Doouss, 1968 , ) . However, the single injection technique was used in these studies and if the dose of injected cortisol was not in complete equilibrium with the endogenous pool, the results obtained may be dependent on the clearance of radioactive cortisol. If part of the injected dose is cleared before equilibrium is reached a falsely high plasma production rate will be obtained. Such a rapid clearance of cortisol is observed in sheep and other domestic animals because of the lack of firm binding to plasma protein (Lindner, 1964; Harrison & Patterson, 1965) . Within limits, incomplete equilibrium of an adminis¬ tered hormone with the body pool should not lead to large errors in the measurements of production rates if these are based on the specific activity of urinary metabolites of cortisol (Laumas, Tait & Tait, 1961) . In order to confirm the previous findings of a high production in advanced breast cancer patients, the production rate of cortisol from its plasma clearance (plasma production rate) and from the specific activities of urinary metabolites (urinary production rate) was (Bush, 1952 Estimation of cortisol production from the specific activity of urinary cortisol All. portion of a 3-day pool was extracted with ethyl acetate (1 equal volume, 2x| volume). The pooled ethyl acetate extract was washed with 0-2 N-NaOH and water as described above. The paper Chromatographie systems and column chroma¬ tography used in the isolation of cortisol were as described above. Two^a liquots of the isolated cortisol were taken for counting and duplicate^a nd ^aliquots with 2 µg. standards were used for the Porter-Silber reaction. Cortisol production was estimated by the formula shown above.
Plasma production rate of cortisol was determined according to the procedure of Jensen et al. (1968 ) .
The method of Few (1961) as modified by Thomas (1965) was used to estimate total 17-OHCS.
RESULTS
The results in five women without cancer are compared with those in four patients with early breast cancer and nine patients suffering from advanced breast cancer with widespread métastases.
The specific activities of three urinary metabolites of cortisol, namely, cortisol, THE and THF are shown in Table 1 . Although in three out of 18 cases, the specific activities of these three metabolites were the same, the specific activity of urinary cortisol was generally higher than that of the two other metabolites. Furthermore, The mean plasma production rate of cortisol and the rate of urinary cortisol production based on urinary cortisol or THF were significantly higher in advanced breast cancer patients than in normal controls: t = 4-4, < 0-01; t = 2-7, < 0-02; t = 2-15, < 0-05 respectively. No other parameters showed significant differences.
The relationship between the plasma and urinary production rates of cortisol is shown in Fig. 1 . There is a highly significant correlation between these two para¬ meters indicating that the higher plasma production rate in advanced breast cancer patients is also reflected in a high urinary production rate of the hormone.
Correlation between the urinary production rate of cortisol based on the specific activities of cortisol, THE and THF The correlation between the production rate of cortisol measured by the specific activities of cortisol, THE and THF is shown in Figs. 2 and 3 . There is a significant correlation between the production rate measured by these three parameters.
The total urinary 17-OHCS levels were plotted against the urinary cortisol rate. There was no significant correlation between the urinary 17-OHCS and plasma or urinary production rates in this series (r = 0-289). Urinary cortisol production rate (mg./24 hr.) Fig. 3  Fig. 2 . The urinary cortisol production rate based on the specific activities of urinary cortisol and tetrahydrocortisone (THE) in patients with early or advanced breast cancer and controls. O, Controls; , early breast cancer; #, advanced breast cancer. The regression line shown is that of THE (y) on cortisol (x). (y = 0-768x-f 7-233; r = 0-582, < 0-02). Fig. 3 . The urinary cortisol production rate based on the specific activities of urinary cortisol and tetrahydrocortisol (THF) in patients with early or advanced breast cancer and controls. O, Controls; , early breast cancer; , advanced breast cancer. The regression line shown is that of THF (y) on cortisol (x). (y = 0-963^+ 4-940; r = 0-671, < 0-01).
DISCUSSION
The plasma production rate was estimated at a time when the secretion of the endogenous hormone was probably maximal. The values obtained for cortisol production based on the plasma clearance of the hormone are therefore higher than those obtained by the urinary method. As in the previous study (Jensen et al. 1968 ) the mean plasma production rate of cortisol was significantly raised in advanced breast cancer and this higher production was reflected in the urine when it was estimated from the specific activity of urinary cortisol or THF. However, there was no significant difference in the rate of cortisol production in the advanced breast cancer patients when the production was calculated from the specific activity of THE.
The highly significant correlation between the plasma and urinary production rate of cortisol indicates that the values obtained by the plasma clearance method are representative of the total daily production and suggests that equilibration of administered cortisol with the body pool was almost complete. Furthermore, since there is a significant correlation between the production rates estimated from the specific activities of urinary cortisol, THE and THF, it is reasonable to assume that these rates are related to the daily production of the hormone, though it is impossible to decide which is the correct rate.
Since the original publication by Cope & Black (1958) of a method for the deter¬ mination of cortisol production based on the specific activities of urinary THE and THF, many workers have used the method, or a modification of it, in determining the production of hormones in normal and abnormal conditions (see Cope, 1965 (Laumas et al. 1961 ; Tait, 1963) in about one-third of the cases it is doubtful whether the values obtained represent the daily production of the hormone accurately. Furthermore, the abnormalities found were not particularly related to patients with breast cancer since they were also observed in controls (see Table 1 and Fukushima et al. 1968 ).
In theory, if the mixing of the injected cortisol with the endogenous pool is com¬ plete and only a small proportion of the injected cortisol was cleared from the plasma before equilibration with the cortisol pool, the specific activities of the three urinary metabolites should be the same. In many cases this was found to be true. Where differences were observed, the specific activity of urinary cortisol was generally higher than that of THE and THF. This could be explained partly on the grounds that mixing was occasionally incomplete. However, it is also possible that the THE and THF are not unique metabolites of the injected hormone and that there is a second precursor of these compounds which is contributing to the total urinary excretion. Furthermore, since the urinary production rates based on the specific activities of cortisol, THE and THF are correlated, such a precursor must also be a precursor of cortisol.
Since the original work of Hechter & Pincus (1954) , it has been accepted that the biosynthetic pathway from pregnenolone to cortisol is by way of progesterone. Recent studies in vivo and in vitro indicate that progesterone plays only a minor role in the cortisol synthesis in the human adrenal gland (Cameron, Beynon & Griffiths, 1968; Whitehouse & Vinson, 1968; Deshpande, Jensen & Doouss, 1969) and that the major pathway appears to be via 17a-hydroxypregnenolone. There is some evidence to suggest that the A5-3/?-hydroxy structure remains intact and that 17a-hydroxyprogesterone is not an obligatory metabolite in the synthesis of cortisol (Deshpande et al. 1969) . If the A5-3/?-hydroxy part of molecule remains intact, one compound which might act as a precursor of cortisol and urinary THE or THF might be 3/?,ll/?,17a,21-tetrahydroxy-pregn-5-en-20-one. Attempts are now being made to identify such a compound in adrenal venous blood.
Finally, there is no correlation between the production of the hormone and its excretion. The lack of correlation does not appear to be related to cancer patients as no correlation was observed in normal subjects (Peterson & Wyngaarden, 1956 ). There is no explanation for this finding at present.
